Coagulation, fibrinolysis and platelet drop in patients undergoing transfemoral transcatheter aortic valve implantation
Catheterization and Cardiovascular Interventions · 2024
DOI: 10.1002/ccd.31199 ↗Kurz gefasst
Fachartikel in der Zeitschrift Catheterization and Cardiovascular Interventions, 2024. Verfasst von Taiga Katayama und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Teikyo University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Fibrinolysis, Blood Coagulation, Transcatheter Aortic Valve Replacement, Femoral Artery. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 17 Literaturangaben.
Abstract (Originalsprache)
Background
Transcatheter aortic valve implantation (TAVI) leads to transient platelet activation and hypercoagulation status, resulting in thrombocytopenia.
Aims
This study investigated the associations of coagulation/fibrinolysis status after transfemoral TAVI with valve type, post‐TAVI thrombocytopenia, and complication of TAVI.
Methods
Thrombin–antithrombin complex (TAT) and fibrin/fibrinogen degradation product (FDP) levels were measured before and 1 h, 1 day, and 2 days after TAVI. A percentage drop in platelet count (DPC) was determined from the pre‐ and lowest post‐procedural values.
Results
SAPIEN 3 (S3) was implanted in 158 patients and Evolut PRO/PRO+ (Evolut) in 117. Both TAT and FDP increased after TAVI. Pre‐TAVI balloon dilatation was generally performed on patients undergoing implantation with Evolut. Peak TAT was then stratified into 4 quartiles (Q1 to Q4). Of all 275 study patients, 69 patients reached ultra‐hypercoagulation status (Q4). S3, TAVI without pre‐balloon dilatation, DPC and bleeding complications were significantly associated with the ultra‐hypercoagulation status after TAVI. TAT was significantly greater 1 h after S3 implantation than Evolut (median [IQR], 43.1 [34.1–59.6] vs. 31.0 [25.0–40.4] ng/mL; p < 0.001). In contrast, FDP levels did not differ between the two at any measurement point. The difference in DPC among the peak TAT quartiles was statistically significant ( p < 0.001). The occurrence of bleeding complications was significantly higher in the group with ultra‐hypercoagulation status (5.8% vs. 1.0%, p = 0.036).
Conclusions
The increase in coagulation status and post‐TAVI thrombocytopenia were significantly greater after S3 implantation. Ultra‐hypercoagulation after TAVI was related to bleeding complications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Teikyo University School of Medicine, Tokyo, Japan.
ORCID-Profile: Naoyuki Yokoyama, Yusuke Watanabe, Hideyuki Kawashima, Ken Kozuma
Zitieren
APA
Katayama, T., Yokoyama, N., Watanabe, Y., Koyama, S., Kawashima, H., Hioki, H., & Kozuma, K. (2024). Coagulation, fibrinolysis and platelet drop in patients undergoing transfemoral transcatheter aortic valve implantation. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.31199
Vancouver
Katayama T, Yokoyama N, Watanabe Y, Koyama S, Kawashima H, Hioki H, et al. Coagulation, fibrinolysis and platelet drop in patients undergoing transfemoral transcatheter aortic valve implantation. Catheterization and Cardiovascular Interventions. 2024. doi:10.1002/ccd.31199
BibTeX
@article{Katayama2024,
author = {Katayama, Taiga and Yokoyama, Naoyuki and Watanabe, Yusuke and Koyama, Shuhei and Kawashima, Hideyuki and Hioki, Hirofumi and Kozuma, Ken},
title = {Coagulation, fibrinolysis and platelet drop in patients undergoing transfemoral transcatheter aortic valve implantation},
journal = {Catheterization and Cardiovascular Interventions},
year = {2024},
doi = {10.1002/ccd.31199}
}
EUVIMED